A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1-Reference-Cited by-同舟云学术

A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

Published:2016-09-20 Issue:1 Volume:4 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Uemura Marc,Faˈak Faisal,Haymaker Cara,McQuail Natalie,Sirmans Elizabeth,Hudgens Courtney W.,Barbara Lydia,Bernatchez Chantale,Curry Jonathan L.,Hwu Patrick,Tetzlaff Michael T.,Diab Adi^ORCID

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-016-0157-6

Reference15 articles.

1. Grover RW. Transient acantholytic dermatosis. Arch Dermatol. 1970;101(4):426–34.

2. Chalet M, Grover R, Ackerman AB. Transient acantholytic dermatosis: a reevaluation. Arch Dermatol. 1977;113(4):431–5.

3. Davis MD, Dinneen AM, Landa N, Gibson LE. Grover's disease: clinicopathologic review of 72 cases. Mayo Clin Proc. 1999;74(3):229–34.

4. Guana AL, Cohen PR. Transient acantholytic dermatosis in oncology patients. J Clin Oncol. 1994;12(8):1703–9.

5. Anforth R, Fernandez-Penas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14(1):e11–18.

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy;Expert Review of Clinical Immunology;2024-03-19

2. An Unusual Trigger of Grover’s Disease (GD);Cureus;2023-06-19

3. Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies;Cancers;2023-06-09

5. Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors;American Journal of Clinical Dermatology;2022-06-16